# EDGAR Filing Document

**Accession Number:** 0001081938
**File Stem:** 0001654954-25-011655
**Filing Date:** 2025-10
**Character Count:** 5566
**Document Hash:** ecdd6c449e4b7ba1e74e3498d8270504
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-25-011655.hdr.sgml**: 20251010

**ACCESSION NUMBER**: 0001654954-25-011655

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 20

**CONFORMED PERIOD OF REPORT**: 20250807

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251010

**DATE AS OF CHANGE**: 20251010

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CANNAPHARMARX, INC.
- **CENTRAL INDEX KEY:** 0001081938
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 274635140
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-27055
- **FILM NUMBER:** 251386954

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 3600
- **STREET 2:** 888 3RD STREET SW
- **CITY:** CALGARY
- **STATE:** DE
- **ZIP:** T2P 5C5
- **BUSINESS PHONE:** 949-652-6838

**MAIL ADDRESS:**
- **STREET 1:** SUITE 3600
- **STREET 2:** 888 3RD STREET SW
- **CITY:** CALGARY
- **STATE:** DE
- **ZIP:** T2P 5C5

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GOLDEN DRAGON HOLDING CO.
- **DATE OF NAME CHANGE:** 20110125

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CCVG, INC.
- **DATE OF NAME CHANGE:** 20101117

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CONCORD VENTURES, INC.
- **DATE OF NAME CHANGE:** 20071003

?xml version='1.0' encoding='ASCII'? canna_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 7, 2025**

---

| |
|:---|
| **CannaPharmaRX, Inc.** |
| **(Exact name of registrant as specified in its charter)** |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **333-251016** | **27-4635140** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**Suite 3600, 888—3rd Street SW**

**Calgary, Alberta, Canada T2P 5C5**

**(Address of principal executive offices, including zip code)**

**(949) 652-6838**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | CPMD | OTC Markets |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events.**

CannaPharmaRX, Inc. ("the "Company") entered into letter agreements with payment schedules to address outstanding amounts due to two significant debtholders of the Company. The Company is entering into the payment schedule as a way to address outstanding debts and avoid additional defaults but retain capital to continue to grow operations and deliver product. Information about the payment schedules was previously included in the Company's 10Q for period ending June 30, 2025, however, the actual schedule agreements were erroneously not included. The Company is filing this 8-k to include the actual payment schedule agreement that were erroneously not included in the exhibits of the Company's 10Q for period ending June 30, 2025.

**Item 9.01 Financial Statements and Exhibits.**

The repayment schedules for the debtholders are being attached as an exhibit herewith.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [1.1](canna_ex11.htm) | [Letter Agreement (Payment Schedule) - A. Tal](canna_ex11.htm)<br>[Payment Schedule (Payment Schedule) - Koze Investments](canna_ex11.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

2<br>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CANNAPHARMARX, INC.** | **CANNAPHARMARX, INC.** |
| October 3, 2025 | By: | /s/ Constantine Nkafu |
|  | Name: | Constantine Nkafu |
|  | Title: | CEO |

---

3<br>

## Exhibit 1.1

**EXHIBIT 1.1**

![](canna_ex11img1.jpg)

![](canna_ex11img2.jpg)

![](canna_ex11img3.jpg)

![](canna_ex11img4.jpg)

![](canna_ex11img5.jpg)